NCT02767349View on ClinicalTrials.gov

Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

June 30, 2017

Conditions
Acute Pain
Interventions
DRUG

MNK-155

2 or 3 tablets initial dose, followed by two tablets every twelve hours

Trial Locations (1)

27710

Duke University Health Systems, Durham

Sponsors

Lead Sponsor

Mallinckrodt
All Listed Sponsors
lead

Mallinckrodt

INDUSTRY

NCT02767349 - Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain | Biotech Hunter | Biotech Hunter